IBANEZ P., BONNET A.M., DEBARGES B., LOHMANN E., TISON F., POLLAK P., AGID Y., DURR A., BRICE
A. and the French Parkinson’s Disease Genetics Study Group.
Causal relation between -synuclein gene duplication and familial Parkinson’s disease.
MALTETE D., NAVARRO S., WELTER M.L., ROCHE S., BONNET A.M., HOUETO J.L., PIDOUX B.,
Subthalamic stimulation in Parkinson’s disease : with or without anesthesia ?
MESNAGE V., HOUETO J.L., BONNET A.M., CLAVIER I., ARNULF I., CATTELIN F., LE FUR G., DAMIER P.,
Neurokinin B, neurotensin and cannabinoid receptor antagonists and Parkinson’s disease.
Clin.Neuropharmacol., 2004, 27(3), 108-110.
PAYOUX P., REMY P., DAMIER P., MILOUDI M., LOUBINOUX I., PIDOUX B., GAURA V., RASCOL O.,
Subthalamic nucleus stimulation reduces abnormal motor cortical overactivity in Parkinson’s disease.
WELTER M.L., HOUETO J.L., BONNET A.M., BEJJANI B.J., MESNAGE V.DORMONT D., NAVARRO S.,
Effects of high-frequency stimulation on subthalamic neuronal activity in Parkinsonian patients.
IBANEZ P., LOHMANN E., POLLAK P., DURIF F., TRANCHANT C., AGID Y., DURR A., BRICE A. for the
French Parkinson’ s Disease Genetics Study Group.
Absence of NR4A2 exon 1 mutations in 108 families with autosomal dominant Parkinson disease. Primary orthostatic tremor and unsteadiness. Centre d'investigation Clinique - Groupe Hospitalier Pitié-Salpêtrière - Batiment Paul Castaigne
47, boulevard de l'Hôpital - 75651 Paris Cedex 13 – France Tél. +33 1 42 16 19 50
POLLAK, P., TISON, F, DESTEE, A., PERE, J.J., SENARD, J.M., DURIF, F., BOURDEIX I., and behalf of the
Clozapine in drug-induced psychosis in Parkinson’s disease : randomized, placebo controlled study with open follow up.
J. Neurol. Neurosurg. Psy., 2004, 75, 689-695.
OLANOW W., AGID Y., MIZUNO Y., ALBANESE A., BONUCELLI U., DAMIER P., DE YEBENES J.,
GERSHANIK O., GUTTMAN M., GRANDAS F., HALLETT M., and al.
Levodopa in the treatment of Parkinson’s disease : Current Controversies.
DORMONT D., RICCIARDI K.G., TANDE D., PARAIN K., MENUEL C., GALANAUD D., NAVARRO S., CORNU
Is the subthalamic nucleus hypointense on T2-Weighted Images ? A correlation study using MR and stereotaxic atlas data.
Am. J. Neuroradiol., 2004, 25, 1516-1523.
CHARFI F., COHEN D., HOUETO J.L., SOUBRIE C., MAZET P.
Tardive dystonia induced by atypical neuroleptics : a case report with Olanzapine. J. of Child and Adolescent
Psychopharmacology, 2004, 14, 1, 151-154.
KREISLER A., STANKOFF B., RIBEIRO M.J., AGID Y., LUBETZKI C., FONTAINE B.
Unexpected aggravation of Parkinson’s disease by a mesencephalic multiple sclerosis lesion.
J. of Neurol., 2004, 215, 12, 1526-1527.
Centre d'investigation Clinique - Groupe Hospitalier Pitié-Salpêtrière - Batiment Paul Castaigne
47, boulevard de l'Hôpital - 75651 Paris Cedex 13 – France Tél. +33 1 42 16 19 50
LIFE SCIENCE Injunction granted in a case between Novartis and Teva By Attorney-at-Law Peter-Ulrik Plesner and Attorney-at-Law Mikkel Vittrup On 18 November 2008 the Eastern Division of the Danish High Court ruled in a case between Novartis and Teva to grant an injunction against Teva's marketing of a generic pharmaceutical product, which contained Valsartan as
Master of Science in Technology and Innovation Management (TIM) In order to be eligible for admission for the Master of Science Program in Technology and Innovation Have a Bachelors' Degree in Engineering (normal y from a Four Year Program) from Tribhuvan University or its equivalent from an institution of recognized standing. Have undergraduate grades significantly above average and not less
IBANEZ P., BONNET A.M., DEBARGES B., LOHMANN E., TISON F., POLLAK P., AGID Y., DURR A., BRICE
A. and the French Parkinson’s Disease Genetics Study Group.
Causal relation between -synuclein gene duplication and familial Parkinson’s disease. 
POLLAK, P., TISON, F, DESTEE, A., PERE, J.J., SENARD, J.M., DURIF, F., BOURDEIX I., and behalf of the
Clozapine in drug-induced psychosis in Parkinson’s disease : randomized, placebo controlled